Canada Health Alliance

Breaking News: FDA Expands Eligibility for Pfizer-BioNTech Covid-19 Booster Dose to Children 5 through 11 Years

The safety of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine in this age group was assessed in approximately 400 children who received a booster dose at least five months (range 5 to 9 months) after completing a two-dose primary series. The most commonly reported side effects were pain, redness and swelling at the injection site, as well as fatigue, headache, muscle or joint pain and chills and fever.

The FDA did not hold a meeting of its Vaccines and Related Biological Products Advisory Committee on today’s action, as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of Pfizer’s EUA request, the FDA concluded that the request did not raise questions that would benefit from additional discussion by committee members. The FDA will make available on its website relevant documents regarding today’s authorization. 

The amendment to the EUA was granted to Pfizer Inc.

* Emphasis Editor’s

Latest articles

Dawn Lester & David Parker … As we have shown in many...
Dawn Lester & David Parker Modern medicine is widely acclaimed as being...
Dawn Lester & David Parker In parts one and two, we showed...
Dawn Lester & David Parker In the three previous parts of this...
Roger Koops For those who may not recall Chicken Little (AKA Henny...
Tristan Coleman Does the latest ‘climate consensus’ study show a genuine agreement...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!